Update on Genentech/Roche Initiation of MANATEE Clinical Study

Leave a Comment / Clinical Trials, Front Page News, Industry Updates /

We are pleased to share an update on Genentech’s, a member of the Roche Group, initiation of MANATEE, a new global Phase 2/3 clinical study that aims to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth in combination with risdiplam, in Spinal Muscular Atrophy (SMA). Why a combination […]

Update on Genentech/Roche Initiation of MANATEE Clinical Study Read More »

New Data Presented at World Muscle Society 2021 Virtual Congress

Leave a Comment / Front Page News, Industry Updates, Research /

This week, new data was presented at the World Muscle Society 2021 Virtual Congress. Check it out below!     Scholar Rock presents two posters featuring additional analyses from the TOPAZ phase 2 trial of Apitegromab: Poster: Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (LBP.10) This

New Data Presented at World Muscle Society 2021 Virtual Congress Read More »

Community Statement from Biogen: New Clinical Study Planned to Evaluate the Potential Benefit of an Investigational Higher Dose of Nusinersen in People with SMA Previously Treated with Evrysdi® (risdiplam)

Leave a Comment / Front Page News, Industry Updates /

Biogen is committed to improving health outcomes for people impacted by spinal muscular atrophy (SMA) and generating data to assess if there are treatment pathways to address potential unmet needs. Today, we are excited to announce our intent to initiate a new global SMA clinical trial called ASCEND to understand whether an investigational higher dose

Community Statement from Biogen: New Clinical Study Planned to Evaluate the Potential Benefit of an Investigational Higher Dose of Nusinersen in People with SMA Previously Treated with Evrysdi® (risdiplam) Read More »

Community Spotlight: Shaakira Thomas and Family

Leave a Comment / Community Awareness, Community Spotlight /

Every August, the spinal muscular atrophy (SMA) community unites, raises awareness, and shows our pride for SMA Awareness Month. This year, Shaakira Thomas and her family chose to go above and beyond by organizing landmark lightings all over the country, all in support Cure SMA’s newborn screening initiatives. Shaakira and her husband, Parris Sr., are parents to Aaliyah,

Community Spotlight: Shaakira Thomas and Family Read More »

Novartis Announces Lift of Partial Clinical Trial Hold, Plans to Initiate a New Study of Intrathecal Zolgensma in Older Patients with SMA

Leave a Comment / Clinical Trials, Front Page News, Industry Updates /

Novartis announced that the U.S. Food and Drug Administration (FDA) has determined that OAV-101 intrathecal (IT) clinical trials for spinal muscular atrophy (SMA) patients may proceed, thereby lifting the partial clinical trial hold initiated in October 2019. The decision to lift the hold was based on data from Novartis’ comprehensive nonclinical toxicology study in non-human

Novartis Announces Lift of Partial Clinical Trial Hold, Plans to Initiate a New Study of Intrathecal Zolgensma in Older Patients with SMA Read More »

Data for Genentech’s Evrysdi Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies with Type 1 SMA

Leave a Comment / Clinical Trials, Front Page News, Industry Updates, Research /

Data from Genentech, a member of the Roche Group, recently announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH Part 2, a pivotal global study evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies aged 1-7 months old with symptomatic Type 1 spinal muscular atrophy (SMA). The study met its primary endpoint

Data for Genentech’s Evrysdi Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies with Type 1 SMA Read More »

Cure SMA Convenes Working Group to Discuss Biomarkers for SMA

Leave a Comment / Front Page News, Research /

The advent of three approved SMN-upregulating therapeutics for spinal muscular atrophy has dramatically changed the natural history of the disease. There are, however, many uncertainties regarding timing of treatment initiation, response to treatment, and long-term outcomes.  The identification of biomarkers, medical indicators that can inform us as to disease status, treatment response, and/or provide information

Cure SMA Convenes Working Group to Discuss Biomarkers for SMA Read More »

Thank You for Another Fantastic Virtual SMA Conference!

Leave a Comment / Conference, Front Page News /

Cure SMA would like to thank everyone who attended the recent 2021 Virtual SMA Conference and 2021 Virtual SMA Research & Clinical Care Meeting. It was an impactful week of workshops, networking, and SMA community engagement. This year’s virtual conference week—the second virtual conference during these pandemic times—hosted nearly 2,500 registrants from over 65 countries. Cure SMA offered

Thank You for Another Fantastic Virtual SMA Conference! Read More »

In Just Three Years, Cure SMA Marks Nationwide Milestone for 85% of U.S. Babies Now Screened at Birth for SMA

Leave a Comment / Advocacy, Front Page News, Our Impact /

The organization’s grassroots efforts give thousands of families new hope by securing widespread, state-by-state screening for SMA at birth Within three years of spinal muscular atrophy (SMA) being added to the federally recommended list of diseases to screen for at birth, Cure SMA is celebrating a significant milestone—85 percent of newborns in the U.S. are now

In Just Three Years, Cure SMA Marks Nationwide Milestone for 85% of U.S. Babies Now Screened at Birth for SMA Read More »

Novartis Data Demonstrate Age-Appropriate Development When Zolgensma Is Used Presymptomatically and Rapid, Clinically Meaningful Efficacy in Symptomatic Children

Leave a Comment / Clinical Trials, Front Page News, Industry Updates, Research /

Novartis recently announced data that reinforce the transformational benefit of Zolgensma® (onasemnogene abeparvovec), an essential, one-time treatment and the only gene therapy for spinal muscular atrophy (SMA). New late-breaker data from the completed two-copy cohort of the Phase 3 SPR1NT clinical trial demonstrate age-appropriate milestone development in presymptomatic children with SMA without respiratory or nutritional support of

Novartis Data Demonstrate Age-Appropriate Development When Zolgensma Is Used Presymptomatically and Rapid, Clinically Meaningful Efficacy in Symptomatic Children Read More »

Scroll to Top